Covid-19 roundup: GSK and Vir reach sotro­vimab sup­ply agree­ment in Sin­ga­pore; J&J vac­cine shows var­ied suc­cess against vari­ants

GSK Sin­ga­pore and Vir Biotech­nol­o­gy have reached an agree­ment with the Sin­ga­pore gov­ern­ment to sup­ply it with a sin­gle-dose mon­o­clon­al an­ti­body for Covid-19.

GSK has sub­mit­ted an ap­pli­ca­tion for reg­u­la­to­ry re­view in the coun­try. Phase III da­ta showed the drug spurred an 85% re­duc­tion in hos­pi­tal­iza­tion or death com­pared to the place­bo. The study in­clud­ed 583 pa­tients, and pre­clin­i­cal da­ta sug­gest­ed that the drug main­tains ac­tiv­i­ty against the Al­pha, Be­ta, Gam­ma and Delta vari­ants.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER